Cargando…
Cancer and Thrombosis: New Treatments, New Challenges
The direct-acting oral anticoagulant (DOAC) has become an alternative to low-molecular-weight heparin (LMWH) for treatment and prophylaxis of venous thromboembolism (VTE) in cancer patients. The clinicians are, however, faced with difficult decisions regarding DOAC treatment: Which patients cannot u...
Autor principal: | Dahm, Anders Erik Astrup |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293316/ https://www.ncbi.nlm.nih.gov/pubmed/34204957 http://dx.doi.org/10.3390/medsci9020041 |
Ejemplares similares
-
Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges
por: Frere, Corinne, et al.
Publicado: (2019) -
Cancer-associated thrombosis (CAT) - New challenges for the hematologist
por: Brækkan, Sigrid
Publicado: (2018) -
Bias in animal studies of estrogen effects on cardiovascular disease: A systematic review and meta‐analysis
por: Friis Berntsen, Christopher, et al.
Publicado: (2021) -
Breast Cancer Treatments: Updates and New Challenges
por: Burguin, Anna, et al.
Publicado: (2021) -
Neutrophils, Cancer and Thrombosis: The New Bermuda Triangle in Cancer Research
por: Langiu, Mélanie, et al.
Publicado: (2022)